As a result of beta cell destruction, islet cell antibodies (ICA) can be demonstrated in the circulation. These antibodies can be detected up to eight years prior to overt IDDM.

Nicotinamide, a vitamin B3 derivative, interferes with the immune mediated beta-cell destruction by reducing the content of FR and NO and thereby reducing their deleterious effects.

At the same time, nicotinamide increases the intracellular NAD pool, thus increasing the energy supply of the cell. Nicotinamide protects against chemically induced as well as spontaneous diabetes in animal models of the disease.

Recently, open clinical studies have suggested that nicotinamide when administered to humans can prevent or delay clinical onset of IDDM.

About the Authors

Reimers JI, Andersen HU, Pociot F. (1994). Nicotinamide and Prevention of Insulin-dependent Diabetes Mellitus. Rationale, Effects, Toxicology and Clinical Experiences ENDIT Group. Ugeskr Laeger 1994 Jan 24;156(4):461-5. Steno Diabetes Center, Gentofte.